AI-Powered Real-World Evidence (RWE) Solutions Market Expands in Oncology and Rare Diseases

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "AI-Powered Real-Worl Evidence (RWE) Solutions Market"-, By Component(Software/Platforms, Services), By Data Source(EHR/EMR Data, Claims Data, Genomics, Wearables/IoT, Patient-Reported Data, Imaging), By Therapeutic Area(Oncology, Neurology, Cardiology, Rare Diseases, Immunology), By End-User (Pharma/Biotech, Payers/PBMs, Hospitals/IDNs, Regulators, CROs), By Deployment Model (Cloud-Based, On-Premise, Hybrid), By Technology (NLP, Computer Vision, Federated Learning, Graph ML), By Application (Drug Development, Regulatory Submissions, Market Access, Precision Medicine), and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2034."

Global AI-Powered Real-World Evidence (RWE) Solutions Market Size is predicted to reach grow at a 14.6 % CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3135

The base of Real-World Evidence (RWE) is Real-World Data (RWD), which comprises information gathered from sources other than controlled clinical trials, such as wearable technology, medical claims, registries, electronic health records (EHRs), and patient-generated data. By offering actionable insights from intricate, varied datasets, these technologies seek to improve patient outcomes, expedite drug discovery, and improve healthcare decision-making. Based on the material at hand, the following provides a thorough overview of AI-powered RWE solutions.

AI-powered, More and more sophisticated and successful pharmaceutical clinical trials are being developed using real-world evidence. Real-world patient data helps trial designers comprehend treatment trends, disease progression, and population heterogeneity in ways that RCTs cannot.AI technologies are now being used by pharmaceutical teams to refine inclusion/exclusion criteria, model trial scenarios, and identify high-yield patient populations. Quicker recruiting, fewer protocol changes, and reduced trial expenditures are made possible by this. In one project, a multinational pharmaceutical corporation optimized trial design using companies. AI-powered analytics capabilities. Through the analysis of thousands of historical trial records and the simulation of several design iterations, the team improved patient stratification and shortened the trial planning time. Early-stage initiatives now have a competitive edge due to an AI-enabled design methodology.

There has been a tremendous advancement in recent years in the definition of how RWE can be included in regulatory filings. The FDA's framework for RWE utilization reflects a higher reliance on real-world data to expedite post-marketing surveillance, label extensions, and therapeutic approvals, while the European Medicines Agency (EMA) promotes adaptive approaches. These frameworks recognize that controlled trial settings may not always accurately reflect how well medications operate in the complex environment of routine clinical practice. RWE is difficult to use in a regulatory setting, though.

Data must adhere to strict quality requirements. It needs to be statistically sound, traceable, and reproducible. Many pharmaceutical teams still view RWE as an ancillary resource rather than a crucial strategic asset. The key to optimizing RWE's potential as it becomes more and more crucial in the drug development lifecycle is integrating it with AI. Pharma companies are ready to help life sciences firms reimagine how they gather, evaluate, and react to real-world data with scalable, domain-grounded, and regulator-aligned solutions.

List of Prominent Players in the AI-Powered Real-World Evidence (RWE) Solutions Market:
• Aetion
• Atropos Health
• ConcertAI
• Envision Pharma Group
• Flatiron Health
• Health Compiler
• Huma
• IQVIA
• Ividence.ai
• Komodo Health
• NVIDIA CLARA
• OM1
• Okra.ai
• Optum
• Owkin
• Panalgo
• Realyze Intelligence
• Syntropy
• Tempus
• Unlearn.AI
• Veradigm
• Other Prominent Players

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics:
Drivers:
Healthcare is moving toward a more quality-oriented future where the focus is on the caliber of services rendered. Many hospitals are aware of the shortcomings of conventional methods in terms of cost-effectiveness and patient care. As a result, healthcare is changing from volume to value-based care, which emphasizes data that is focused on outcomes. Using healthcare innovations to improve quality of life is known as value-based care, according to the American Journal of Managed Care. Sets of common parameters used to evaluate the cost-effectiveness and value of these interventions are used to identify them. As a result, the majority of hospitals are moving toward value-based care as they realize how unproductive traditional methods to patient care are.

Challenges:
The market for real-world evidence solutions is growing slowly because there aren't enough qualified workers to manage sophisticated digital systems. In the clinical research sector, there is a shortage of skilled workers compared to the demand, which hinders the use of sophisticated and challenging software in clinical trials.

Regional Trends:
North America has the largest market share during the forecast period. The growing number of payers utilizing Real World Data (RWD), a supportive regulatory environment, an increase in RWE service providers, and a growing number of pharmaceutical companies implementing RWE solutions for drug approval procedures are all factors propelling the real-world evidence solutions market in the United States. The substantial market share in this area is driven by a number of variables, such as the growing number of chronic illnesses, stricter medication approval laws, the accessibility of electronic datasets, improvements in the healthcare sector, and the expanding amount of big data in healthcare.

This market share is further supported by government efforts that encourage the deployment of RWE technology. However, Asia Pacific is the fastest-growing region. Numerous contract research and manufacturing businesses in nations like China and India, as well as growing government pushes for the adoption of RWE studies, are responsible for the expansion. The industry is expected to increase as a result of rising demand for improved healthcare services. Furthermore, by forming alliances or diversifying their product lines, big firms are bolstering the market expansion in the area.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/3135

Recent Developments:
• In Jan 2025, Atropos Health and xCures declared a collaboration to use RWE-based analytics to improve patient care. Through this collaboration, the businesses will use AI, the xCures Platform, and the Atropos EvidenceTM Network to create and distribute highly proven prognostic and decision support tools to healthcare providers throughout the healthcare ecosystem. The collaboration marks a major advancement in the analysis and use of RWE using AI. Atropos Health and xCures will collaborate to create solutions that provide traceable, source-verified insights straight into clinical processes from raw clinical notes, analytics, and imaging data.
• In July 2021, Syneos Health and Aetion declared a collaboration to offer analytics-driven solutions and regulatory-grade data to enhance medication development and improve patient outcomes. The collaboration combines Aetion Evidence Platform (AEP) with Syneos Health's in-house data collecting and research tools to produce evidence through real-world evidence (RWE) analytics and patient data curation. Biopharmaceutical companies can reduce risk through evidence-based decision-making, speed up product development and patient access to new therapies, and prove value to a wide range of healthcare stakeholders, including patients, regulators, payers, and healthcare providers, with Syneos Health's offerings, such as its Biopharmaceutical Acceleration Model, Dynamic Assembly, and RWE Solutions.

Global AI-Powered Real-World Evidence (RWE) Solutions Market - By Component
• Software/Platforms
• Services
Global AI-Powered Real-World Evidence (RWE) Solutions Market - By Data Source
• EHR/EMR Data
• Claims Data
• Genomics
• Wearables/IoT
• Patient-Reported Data
• Imaging
Global AI-Powered Real-World Evidence (RWE) Solutions Market - By Therapeutic Area
• Oncology
• Neurology
• Cardiology
• Rare Diseases
• Immunology
Global AI-Powered Real-World Evidence (RWE) Solutions Market - By End-User
• Pharma/Biotech
• Payers/PBMs
• Hospitals/IDNs
• Regulators
• CROs
Global AI-Powered Real-World Evidence (RWE) Solutions Market - By Deployment Model
• Cloud-Based
• On-Premise
• Hybrid
Global AI-Powered Real-World Evidence (RWE) Solutions Market - By Technology
• NLP
• Computer Vision
• Federated Learning
• Graph ML
Global AI-Powered Real-World Evidence (RWE) Solutions Market - By Application
• Drug Development
• Regulatory Submissions
• Market Access
• Precision Medicine
Global AI-Powered Real-World Evidence (RWE) Solutions Market - By Region
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/ai-powered-real-world-evidence-rwe-solutions-market/3135

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.